Funded through the Innovative Medicines Initiative, the public-private Real world outcomes across the Alzheimer's Disease spectrum for better care: Multi-modal data Access Platform (ROADMAP) project brought together 26 organisations led by Novartis and coordinated by the University of Oxford.
One of the partnership's main aspirations was to support the identification and integration of realworld data across multiple sources and countries. Through that, it intended to support opportunities for the development of evidence for the reimbursement and access of new technologies for the treatment of Alzheimer's disease (AD), ultimately aiming to drive healthcare systems towards better care and data capture.
The consortium therefore collaboratively developed this 3D 'heat map' assessment. It allows the visualisation of the different data sources and how they are able to capture different AD-outcomes together with their relevance for the different disease stages. Users can switch between the perspectives of people with dementia, carers and health professionals. Enabling the visualisation of the AD-related data availability in different types of European data
sources and the intrinsic gaps, has proven to be a powerful tool for the design, planning and validation of the models and strategies used to guide future recommendations to enhance AD research.
Through these efforts, ROADMAP helps address the challenge of how best to inform clinical and health-policy decisions by studying how to build a population-based integrated data environment and enabling its visualisation. The online version of the Data Cube is available here: https://datacube.roadmap-alzheimer.org.
The Data Cube is an important outcome of the ROADMAP project as it provides a much needed, overarching picture of priority outcomes, across the disease stages, and whether data is available. It helps to identify gaps in the evidence and provides a useful tool for regulatory and HTA purposes. - Dr Jacoline Bouvy, Senior Scientific Adviser, NICE